This study is being performed to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart. AZD5672 will be compared against a drug (moxifloxacin - a licensed antibiotic) known to have a detectable but safe change on the electrical conduction of the heart.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
64
12 x 50mg tablet, oral, single dose
1 x 400mg capsule, oral, single dose
12 x matched to AZD5672 50 mg tablet
Research Site
London, United Kingdom
Evaluate time-matched QTcF intervals of single dose AZD5672 600mg compared to placebo.
Time frame: Up to 24 hours postdose
Evaluate time-matched QTcF Intervals of single dose AZD5672 150mg compared to placebo.
Time frame: Up to 24 hours postdose
To evaluate the change in time matched ECG parameters (QTcB, QTcX, RR, PR and QRS) of single dose AZD5672 600mg and 150mg compared to placebo
Time frame: Up to 24 hours postdose
To further evaluate the safety and tolerability of single dose AZD5672 600mg and 150mg
Time frame: Adverse events assessed throughout the whole study. Safety monitoring (BP, safety blood samples and ECG) conducted frequently throughout study and up to 72 hours post dose on treatment visits.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
3 x 50mg tablet, oral. single dose
9 x matched to AZD5672 50mg tablet
1 x matched to Moxifloxacin capsule